title: Wider benefits of leukodepletion of blood products.
authors.forename: J A
authors.initials: JA
authors.lastname: Copplestone
authors.forename: P
authors.initials: P
authors.lastname: Williamson
authors.forename: D R
authors.initials: DR
authors.lastname: Norfolk
authors.forename: G R
authors.initials: GR
authors.lastname: Morgenstern
authors.forename: J Z
authors.initials: JZ
authors.lastname: Wimperis
authors.forename: L M
authors.initials: LM
authors.lastname: Williamson
mesh_terms: D000208:Acute Disease; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001803:Blood Transfusion / Q000379:methods*; D016026:Bone Marrow Transplantation; D002469:Cell Separation / Q000379:methods*; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D005374:Filtration; D006801:Humans; D007114:Immunization; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D007962:Leukocytes / Q000276:immunology; D015993:Life Tables; D011446:Prospective Studies; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D003561:Cytarabine